Latest Features

LATEST ARTICLES

Cancer Patients May Fall Prey to Illegitimate Online Pharmacies

By

Tori Rodriguez, MA, LPC, AHC

Publish Date February 3, 2023

High drug prices and ongoing shortages may prompt cancer patients to buy treatments online and fall prey to illegitimate pharmacies.

ASH 2022: MCL Trials Break New Ground, May Change Practice

By

Leah Lawrence

Publish Date January 30, 2023

Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.

Aggregating Data Hides Cancer Disparities Affecting Asian and NHPI Patients in the US

By

Tori Rodriguez, MA, LPC, AHC

Publish Date January 27, 2023

Aggregated data can hide disparities in cancer incidence and outcomes among Asian and Native Hawaiian/Pacific Islander patients in the US.

ACS Report Shows Prostate Cancer on the Rise, Cervical Cancer on the Decline

By

Jen Smith

Publish Date January 12, 2023

A report from the American Cancer Society reveals trends in cancer incidence and mortality over time and includes projections for 2023.

Improving End-of-Life Discussions With Cancer Patients

By

Tori Rodriguez, MA, LPC, AHC

Publish Date January 6, 2023

Timely discussions about end-of-life preferences can ensure patients with advanced cancer receive care that aligns with their goals, experts say.

ASH 2022: Promising Results in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

By

Carina Storrs, PhD

Publish Date January 4, 2023

The MonumenTAL-1, MajesTEC-2, OPTIMUM/MUKnine, and GMMG-CONCEPT trials have shown promising results for patients with newly diagnosed or relapsed/refractory multiple myeloma.

AML Research From ASH 2022: Novel Combinations and Evidence That “Less is More”

By

Tori Rodriguez, MA, LPC, AHC

Publish Date January 3, 2023

AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.

CAR-T Therapy in Pediatric Leukemia: Past, Present, and Future

By

Heather Stefanski, MD, PhD

Publish Date January 3, 2023

Prior to the introduction of CAR T-cell therapy, pediatric patients with ALL had limited treatment options for relapsed or refractory disease.

ASH 2022: New Findings in CLL

By

Victoria Forster, PhD

Publish Date December 28, 2022

Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.

SABCS 2022: Trials Show Improved Outcomes in HR+, HER2- Breast Cancer

By

Alan P. Lyss, MD

Publish Date December 21, 2022

The CAPItello-291, monarchE, RIGHT Choice, and EMERALD trials have shown favorable outcomes for patients with HR+, HER2- breast cancer.

ASH 2022: Trials Show Promising Results in Follicular Lymphoma

By

Jonathan Goodman, MPhil

Publish Date December 20, 2022

Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.

Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC

By

Alan P. Lyss, MD

Publish Date December 16, 2022

Differences in tumor characteristics could explain sex- and race-based disparities in patients with metastatic non-small cell lung cancer.

Recognizing Radiation Therapy as Both Cause and Treatment for Cancer Pain

By

Bryant Furlow

Publish Date December 5, 2022

Estimates vary, but research has suggested that roughly 60% of patients undergoing cancer therapy experience pain.

Medicine vs Food: The Patient Care Dilemma of Financial Toxicity

By

Jody A. Charnow

Publish Date November 23, 2022

Physicians are calling on colleagues to bring up the cost of care and its potential impact when discussing treatment options with patients.

Up to 10% of Early-Onset mCRC Cases May Be Driven by Undiagnosed IBD

By

Alan P. Lyss, MD

Publish Date November 15, 2022

As many as 10% of early-onset metastatic colorectal cancer cases may be attributable to undiagnosed inflammatory bowel disease, a study suggests.